Agios Pharmaceuticals Stock Rises 13% After Strong Q1 Earnings Report
Agios Pharmaceuticals (NASDAQ: AGIO) stock surged 13% following its first-quarter earnings report, driven by strong revenue growth from its drug Aqvesme. The company reported $20.7 million in revenue, up from $8.7 million in the same period last year, though it still reported a net loss. The stock's performance was influenced by positive market reception of its new drug and its potential for additional indications.
Topics: earnings report FDA approval pharmaceuticals revenue growth stock price movement